onc Videos

Videos

Helena Yu, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Videos

Combating Resistance to EGFR Tyrosine Kinase Inhibitors in Patients With Lung Cancer

05/17/2023

At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.

At the 2023 Great Debates and...

05/17/2023

Oncology

Kim Norris, Lung Cancer Foundation of America

Videos

Understanding and Employing Patient Advocacy

05/16/2023

At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...

At the 2023 Great Debates and...

05/16/2023

Oncology

Videos

Should ASCT be Standard of Care for Frontline Treatment of Patients With Multiple Myeloma?

05/15/2023

C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD,...

05/15/2023

Oncology

Michael Goodheart, MD, University of Iowa, Iowa City, Iowa

Videos

Identifying Effective Treatment Combinations for Low-Grade Serous Ovarian Cancer

05/12/2023

Michael Goodheart, MD, and Adam Dupuy, PhD, discuss the use of CRISPR technology to identify new potential treatment combinations for low-grade serous ovarian cancer.

Michael Goodheart, MD, and Adam...

05/12/2023

Oncology

BJ Rimel, MD, Cedar Sinai Medical Center, Los Angeles, California

Videos

05/12/2023

At the SGO Annual Meeting on Women’s Cancer BJ Rimel, MD, covers cancer-related concerns for transgender and special patient populations.

At the SGO Annual Meeting on...

05/12/2023

Oncology

Aaron Praiss, MD, Memorial Sloan Kettering Cancer Center, New York, New York

Videos

Surgical Stress May Promote IL-6–Driven Tumor Progression in High-Grade Serous Ovarian Cancer

05/11/2023

At the SGO Annual Meeting on Women’s Cancer, Aaron Praiss, MD discusses the role surgical stress can play in promoting IL-6–driven tumor progression in high-grade serous ovarian cancer.

At the SGO Annual Meeting on...

05/11/2023

Oncology

Videos

ASCT as the Continued Standard of Care in Frontline Multiple Myeloma Therapy

05/10/2023

Amrita Krishnan, MD, participated in a debate about whether high-dose chemotherapy followed by autologous stem cell transplant after completion of induction therapy is the optimal frontline therapy for patients with multiple myeloma.

Amrita Krishnan, MD,...

05/10/2023

Oncology

Videos

Strategies for Diagnosing and Treating Patients With Amyloidosis

05/10/2023

Michael Rosenzweig, MD, shares insights on strategies for diagnosing and treating patients with various subtypes of amyloidosis.

Michael Rosenzweig, MD, shares...

05/10/2023

Oncology

Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan

Videos

Novel Immunomodulatory Virus CARG-2020 for Recurrent Ovarian Cancer

05/10/2023

At the SGO Annual Meeting on Women’s Cancer, Ayesha Alvero, MD, discusses CARG-2020, and how it may be used to restore immunosurveillance and establish anti-tumoral immunological memory among patients with ovarian cancer.

At the SGO Annual Meeting on...

05/10/2023

Oncology

Rebekah Peplinski, graduate research assistant and PhD candidate, University of Iowa, Iowa City, Iowa

Videos

Identifying Oncogenic Drivers Related to Tumor Progression in High-Grade Ovarian Cancer

05/08/2023

At the SGO Annual Meeting on Women’s Cancer, Rebekah Peplinski, PhD candidate, discusses the potential role of Sleeping Beauty mutagenesis for identifying and understanding genes related to tumor progression in high-grade ovarian cancer.

At the SGO Annual Meeting on...

05/08/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology